Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66885-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- PRMT2 antibody
- Antibody type
- Monoclonal
- Description
- PRMT2 antibody (Cat. #66885-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, mouse, rat and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1F1B9
- Vial size
- 20ul, 150ul
Submitted references The antidepressant effects of protein arginine methyltransferase 2 involve neuroinflammation.
PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression.
Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5.
Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.
Liu S, Zhang B, Guo H, Ding Z, Hou W, Hu X, Wang Y, Tan W, Zhou S
Neurochemistry international 2024 Jun;176:105728
Neurochemistry international 2024 Jun;176:105728
PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression.
Li Z, Chen C, Yong H, Jiang L, Wang P, Meng S, Chu S, Li Z, Guo Q, Zheng J, Bai J, Li H
Cell death & disease 2023 May 12;14(5):322
Cell death & disease 2023 May 12;14(5):322
Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5.
Zhang Q, Yang R, Tian Y, Ge S, Nan X, Zhu S, Dong S, Zhang B
Basic & clinical pharmacology & toxicology 2022 Jul;131(1):18-33
Basic & clinical pharmacology & toxicology 2022 Jul;131(1):18-33
Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.
Tian Y, Yang W, Yang R, Zhang Q, Hao L, Bian E, Yang Y, Huang X, Wu Y, Zhang B
Toxicology and applied pharmacology 2022 Jan 15;435:115829
Toxicology and applied pharmacology 2022 Jan 15;435:115829
No comments: Submit comment
No validations: Submit validation data